Palogic Value Management L.P. Makes New Investment in Aspen Aerogels, Inc. $ASPN

Palogic Value Management L.P. acquired a new position in Aspen Aerogels, Inc. (NYSE:ASPN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 185,589 shares of the construction company’s stock, valued at approximately $1,177,000. Palogic Value Management L.P. owned approximately 0.22% of Aspen Aerogels at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ASPN. Bank of America Corp DE acquired a new stake in shares of Aspen Aerogels during the 2nd quarter worth approximately $1,602,000. Odyssean LLC acquired a new stake in Aspen Aerogels in the second quarter worth $265,000. Man Group plc bought a new stake in Aspen Aerogels in the second quarter valued at $572,000. Hsbc Holdings PLC acquired a new position in shares of Aspen Aerogels during the second quarter valued at about $86,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Aspen Aerogels during the second quarter valued at about $131,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Aspen Aerogels Price Performance

ASPN stock opened at $5.21 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.24 and a current ratio of 2.52. The business has a 50-day simple moving average of $5.45 and a two-hundred day simple moving average of $4.63. The company has a market capitalization of $432.38 million, a P/E ratio of -3.41 and a beta of 2.99. Aspen Aerogels, Inc. has a 52-week low of $2.30 and a 52-week high of $9.35.

Aspen Aerogels (NYSE:ASPN) last issued its quarterly earnings data on Thursday, August 6th. The construction company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Aspen Aerogels had a negative return on equity of 31.12% and a negative net margin of 62.45%.The firm had revenue of $49.85 million during the quarter, compared to the consensus estimate of $42.42 million. Aspen Aerogels has set its Q3 2026 guidance at -0.110–0.070 EPS. Research analysts expect that Aspen Aerogels, Inc. will post -0.69 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on ASPN. Wall Street Zen downgraded Aspen Aerogels from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Roth Capital reaffirmed a “buy” rating and set a $7.75 price target on shares of Aspen Aerogels in a research note on Friday, August 7th. Barclays raised their price objective on Aspen Aerogels from $4.00 to $5.00 and gave the company an “underweight” rating in a research note on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aspen Aerogels in a report on Wednesday, June 24th. Finally, B. Riley Financial reaffirmed a “buy” rating on shares of Aspen Aerogels in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.94.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.